🔍

AUROPHARMA - Aurobindo Pharma

📊 NSE: AUROPHARMA 🏢 Pharmaceuticals - Indian - Bulk Drugs & Formln 📅 Last Updated: 12/13/2025 18:43

📢 Recent Corporate Announcements

Aurobindo Pharma to Buyback Shares Worth ₹800 Crore at ₹1,475 Per Share

🟢 POSITIVE ⭐ 8/10

OTHER 📅 21 Apr 2026, 04:03 PM

Aurobindo Pharma has announced a buyback of up to 54,23,728 equity shares via the tender offer route at a price of ₹1,475 per share. The total buyback size is ₹800 crore, representing approximately 0.93% of the total outstanding equity shares. The offer is scheduled to open on April 23, 2026, and close on April 29, 2026, for shareholders who held stock as of the April 17 record date. Small shareholders have been offered a favorable entitlement ratio of 7 shares for every 61 shares held.

Buyback of 54,23,728 shares at a fixed price of ₹1,475 per share via tender route
Total outlay of ₹800 crore represents 2.62% of consolidated net worth as of March 2025
Entitlement ratio for small shareholders is 7:61; General category is 2:249
Offer period is set from April 23, 2026, to April 29, 2026
Settlement of bids expected to be completed by May 7, 2026

💡 Eligible shareholders should consider tendering their shares to take advantage of the ₹1,475 buyback price, especially if it remains at a premium to the market price. Small shareholders should particularly note their higher entitlement ratio for potential short-term gains.

Aurobindo Pharma Receives USFDA Approval for OTC Cough Syrup; Market Size $138 Million

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 17 Apr 2026, 06:34 PM

Aurobindo Pharma has secured final USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC), a generic version of Delsym. The product targets a US market valued at approximately $138 million for the 12 months ending February 2026. Production is slated for the APL Healthcare Unit-IV facility with a commercial launch expected in Q2FY27. This milestone increases the company's total USFDA approvals to 580, reinforcing its strong position in the US generic market.

Final USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension (OTC) 30 mg/5 mL.
Addresses an estimated US market size of $138 million based on Nielsen data for the year ending Feb 2026.
Commercial launch is scheduled for Q2FY27 from the APL Healthcare Unit-IV facility.
Total USFDA portfolio now comprises 580 approvals, including 557 final and 23 tentative approvals.

💡 This approval strengthens Aurobindo's US OTC pipeline and provides revenue visibility for FY27. Investors should maintain a positive outlook as the company continues to leverage its manufacturing scale to capture market share in the US generic space.

Aurobindo Pharma Receives USFDA Approval for Glycerol Phenylbutyrate; Market Size $50.2M

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 17 Apr 2026, 10:40 AM

Aurobindo Pharma has received final USFDA approval for Glycerol Phenylbutyrate Oral Liquid (1.1 g/mL), a generic version of Ravicti. The product is indicated for the chronic management of patients with urea cycle disorders and will be launched immediately. The addressable market for this product is estimated at US$ 50.2 million for the twelve months ending February 2026. This approval further strengthens Aurobindo's extensive US portfolio, bringing its total USFDA ANDA approvals to 579.

Final USFDA approval received for Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL.
Estimated annual market size of US$ 50.2 million according to IQVIA MAT February 2026 data.
The product will be manufactured at the company's Unit-III facility and launched immediately.
Aurobindo now holds a total of 579 ANDA approvals, including 556 final and 23 tentative approvals.

💡 Investors should monitor the successful commercialization of this niche product as it contributes to the company's high-margin US generics business. The immediate launch and moderate market size provide a steady incremental revenue stream for the company.

Aurobindo Pharma Subsidiary to Invest $150-175M for 60KL Biologics Facility for MSD

🟢 POSITIVE ⭐ 8/10

EXPANSION 📅 15 Apr 2026, 04:07 PM

Aurobindo Pharma's subsidiary, TheraNym Biologics, has expanded its contract manufacturing (CMO) agreement with Merck Sharp & Dohme (MSD) Singapore. The company will establish a greenfield project, 'Unit 2', involving an investment of USD 150 million to USD 175 million. This facility will house a large-scale mammalian Drug Substance manufacturing unit with a total capacity of 60,000 liters. This move significantly strengthens Aurobindo's footprint in the high-growth biologics CMO sector and deepens its strategic partnership with a global pharmaceutical leader.

Investment of USD 150 million to USD 175 million for a new greenfield manufacturing facility
Installation of mammalian cell culture bioreactors with an aggregate capacity of 60,000 liters (60 KL)
Expansion of the existing CMO relationship with Merck Sharp & Dohme (MSD) initiated in May 2024
Development of 'Unit 2' to include requisite downstream purification infrastructure for Drug Substance production

💡 Investors should view this as a strategic positive for long-term growth in the high-margin biologics space. Monitor the execution and commissioning timelines of the greenfield project as it represents a significant capital commitment.

Aurobindo Pharma Submits SEBI Regulation 74(5) Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 04:24 PM

Aurobindo Pharma has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing confirms that the Registrar and Share Transfer Agent, KFin Technologies Limited, has processed all dematerialization and rematerialization requests for the quarter ended March 31, 2026. This process ensures that physical share certificates are converted to electronic form and vice versa in accordance with regulatory timelines. This is a standard administrative procedure required for all listed companies in India and does not reflect any change in the company's fundamentals.

Compliance certificate submitted for the quarter ended March 31, 2026.
Confirmation received from Registrar and Share Transfer Agent (RTA) KFin Technologies Limited.
Verification that dematerialized securities are listed on the National Stock Exchange and BSE.
Adherence to SEBI (Depositories and Participants) Regulations, 2018, confirmed by the Company Secretary.

💡 No action is required from investors as this is a routine regulatory filing. Investors should continue to monitor the company's operational performance and upcoming financial results.

Aurobindo Pharma Extends 26% Stake Buy in Swarnaakshu Solar to June 30, 2026

🟡 NEUTRAL ⭐ 3/10

M&A 📅 30 Mar 2026, 05:44 PM

Aurobindo Pharma has announced a delay in its plan to acquire a 26% stake in Swarnaakshu Solar Power Private Limited. Originally scheduled for completion by March 31, 2026, the timeline has now been extended to June 30, 2026. This extension is due to pending state government approvals required for setting up the captive solar power plant. The acquisition is part of the company's long-term strategy to secure renewable energy through a captive power purchase agreement.

Acquisition of up to 26% equity stake in Swarnaakshu Solar Power Private Limited.
Completion deadline extended from March 31, 2026, to June 30, 2026.
Delay attributed to pending state government approvals for the captive solar project.
Investment is linked to a captive solar power purchase agreement for operational efficiency.

💡 This is a minor administrative update regarding the company's green energy initiatives and does not impact core pharmaceutical operations. No immediate action is required as the delay is non-material to the company's financial health.

Aurobindo Pharma Shareholders Approve Dr. Punita Kumar Sinha as Director with 98.96% Majority

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 30 Mar 2026, 12:21 PM

Aurobindo Pharma Limited has announced the successful passage of a special resolution to appoint Dr. (Mrs.) Punita Kumar Sinha as an Independent Director. The resolution was passed via postal ballot with a significant majority of 98.96% of the votes cast in favor. The appointment is for a three-year term effective from February 9, 2026, to February 8, 2029. Total voter participation was high, with 513.4 million votes polled, representing 88.40% of the total equity shares.

Special resolution for the appointment of Dr. Punita Kumar Sinha passed with 98.96% majority.
Total votes polled amounted to 513,445,001, representing 88.40% of the total share capital.
The appointment is for a fixed term of 3 consecutive years ending February 8, 2029.
Promoter and Promoter Group showed 100% voting participation and unanimous support for the resolution.

💡 The high level of shareholder consensus for this appointment reflects strong confidence in the company's governance. Investors should view this as a routine but positive reinforcement of the board's independent oversight.

Aurobindo Pharma Subsidiary CuraTeQ Partners with STADA for Biosimilars in EU

🟢 POSITIVE ⭐ 7/10

EXPANSION 📅 25 Mar 2026, 04:56 PM

CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma, has entered into a marketing and distribution agreement with STADA Arzneimittel AG. The agreement covers two EMA-approved biosimilars developed by CuraTeQ for select European Union territories, including major markets like France and Germany. This partnership aims to leverage STADA's established distribution network to drive revenue growth and expand market reach for Aurobindo's biosimilar portfolio. Although the company classifies this as a non-material event, it represents a strategic move into the high-value European biologics market.

Agreement with STADA Arzneimittel AG for marketing and distribution in select EU territories.
Focuses on two EMA-approved biosimilars developed by wholly owned subsidiary CuraTeQ Biologics.
Target markets include major European economies such as France and Germany.
New brand names will be created and registered specifically for each biosimilar product.

💡 Investors should monitor the commercial launch and revenue ramp-up from these biosimilars as they represent a shift toward higher-margin complex products. This partnership validates the company's R&D capabilities in the biologics space.

Aurobindo Pharma to Close Trading Window from April 1, 2026, for FY26 Annual Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 23 Mar 2026, 05:54 PM

Aurobindo Pharma Limited has announced the closure of its trading window for all designated persons starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of audited financial results for the fiscal year ending March 31, 2026. The trading window will remain closed until 48 hours after the financial results are officially declared to the stock exchanges. The specific date for the board meeting to approve these results will be communicated by the company in due course.

Trading window closure effective from April 1, 2026, for all designated persons and their relatives.
Closure pertains to the Audited Financial Results for the financial year ending March 31, 2026.
Restriction remains in place until 48 hours after the official announcement of the results.
Compliance follows the Company's Internal Code of Conduct and SEBI Insider Trading Regulations.

💡 No action is required as this is a routine regulatory filing. Investors should look out for the upcoming announcement regarding the board meeting date for the FY26 earnings release.

Aurobindo Pharma's Unit-V API Facility Receives VAI Status from US FDA; Inspection Closed

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 20 Mar 2026, 10:00 AM

Aurobindo Pharma's wholly owned subsidiary, Apitoria Pharma Private Limited, has received an Establishment Inspection Report (EIR) for its Unit-V API manufacturing facility in Telangana. The US FDA has classified the facility as 'Voluntary Action Indicated' (VAI) following an inspection conducted in December 2025. This classification effectively closes the inspection process which had previously resulted in three observations. This development is a positive step in maintaining regulatory compliance for the company's API production and ensures continued supply to the US market.

US FDA inspected the Unit-V API facility from December 1 to December 12, 2025
The inspection initially resulted in a Form 483 with 3 observations
The facility has now been classified as Voluntary Action Indicated (VAI) by the US FDA
The US FDA has officially closed the inspection for this manufacturing unit

💡 Investors should view this as a positive development that reduces regulatory uncertainty regarding the company's API supply chain. This clearance supports the company's manufacturing stability and export potential to the US.

Aurobindo Pharma's Eugia Unit-II Classified as OAI by US FDA Following 9 Observations

🔴 NEGATIVE ⭐ 7/10

REGULATORY 📅 17 Mar 2026, 04:26 PM

The US FDA has classified Unit-II of Eugia Pharma Specialities, a wholly-owned subsidiary of Aurobindo Pharma, as 'Official Action Indicated' (OAI). This follows an inspection conducted from November 3 to November 14, 2025, which resulted in 9 observations via Form 483. While the company states it does not foresee an immediate business impact, an OAI status typically delays new product approvals from the facility until regulatory concerns are addressed. Investors should monitor the remediation process closely as this facility is a key part of the company's specialty portfolio.

US FDA classifies Eugia Pharma Unit-II in Bhiwadi, Rajasthan as 'Official Action Indicated' (OAI)
The classification follows an inspection conducted between November 3 and November 14, 2025
The inspection originally resulted in the issuance of a Form 483 with 9 specific observations
OAI status may lead to the withholding of new drug approvals (ANDAs) from this specific manufacturing site
Management currently anticipates no immediate material impact on existing business operations

💡 Investors should exercise caution as OAI status can escalate to Warning Letters or Import Alerts if remediation is deemed insufficient. Monitor management commentary regarding the timeline for re-inspection and potential delays in the specialty product pipeline.

Aurobindo Pharma Faces ₹77.6 Cr GST Demand and Equal Penalty; To Appeal in GSTAT

🔴 NEGATIVE ⭐ 6/10

LEGAL 📅 13 Mar 2026, 12:54 PM

Aurobindo Pharma has received an order from the GST Appellate Authority confirming a tax demand of ₹77.61 crore and an equivalent penalty of ₹77.61 crore. The dispute pertains to alleged excess IGST refunds and non-reversal of Input Tax Credit (ITC) for the period between July 2017 and March 2020. While the authority dropped the interest demand on ITC reversal, the primary tax and penalty were upheld. The company has already paid ₹23.72 crore under protest and intends to challenge the ruling at the GST Appellate Tribunal (GSTAT).

GST demand of ₹77.61 crore confirmed along with a matching penalty of ₹77.61 crore.
Issues involve excess IGST refund (CIF vs FOB) and non-reversal of ITC under Rule 37 for FY 2017-2020.
Company has already deposited ₹23.72 crore under protest and reversed ₹8.78 crore in ITC.
Appellate Authority dropped the demand for interest on ITC reversal while upholding other charges.
Aurobindo Pharma plans to file an appeal before the Goods and Services Tax Appellate Tribunal (GSTAT).

💡 Investors should monitor the outcome of the GSTAT appeal as the total potential liability exceeds ₹150 crore. While the company maintains there is no material impact, persistent tax litigation can weigh on short-term sentiment.

Aurobindo Pharma Subsidiary Unit-IV Receives VAI Status from US FDA

🟢 POSITIVE ⭐ 7/10

REGULATORY 📅 12 Mar 2026, 09:49 AM

Aurobindo Pharma's wholly owned subsidiary, APL Healthcare Limited, has received an Establishment Inspection Report (EIR) for its Unit-IV facility in Andhra Pradesh. The US FDA has classified the facility as 'Voluntary Action Indicated' (VAI), effectively closing the inspection that took place in December 2025. This follows the initial issuance of a Form 483 with 5 observations at the conclusion of the audit. The VAI classification is a positive outcome, indicating that the regulatory hurdles for this specific unit are resolved for the current cycle.

US FDA inspected APL Healthcare Unit-IV from December 8 to December 17, 2025
The inspection initially resulted in a Form 483 containing 05 observations
Facility has now been classified as Voluntary Action Indicated (VAI) by the US FDA
The receipt of the EIR signifies that the regulatory inspection for this unit is now officially closed
Unit-IV is located in SPSR Nellore District, Andhra Pradesh, and is a 100% subsidiary of Aurobindo Pharma

💡 Investors should view this as a positive development as it clears a regulatory hurdle for a key manufacturing unit. This reduces compliance risk and paves the way for potential new product approvals from this facility.

Aurobindo Pharma to Host Investor Group Plant Visit in Vizag and Kakinada on March 16

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Mar 2026, 01:22 PM

Aurobindo Pharma has scheduled an in-person plant visit for an analyst and investor group on March 16, 2026. The visit will take place at the company's facilities in Vizag and Kakinada from 9:00 AM to 5:00 PM IST. This event allows institutional investors to gain direct insights into the company's manufacturing capabilities and operational scale. The company clarified that no unpublished price sensitive information (UPSI) will be disclosed during these interactions.

Scheduled plant visit for analysts and investor groups on March 16, 2026
The visit will cover manufacturing facilities located in Vizag and Kakinada
The interaction is scheduled for a full day, from 09:00 AM to 05:00 PM IST
Company confirms that no unpublished price sensitive information (UPSI) will be shared

💡 No immediate action is required as this is a routine investor relations event. Investors should monitor for any post-visit reports from participating analysts regarding operational efficiency.

Aurobindo Pharma Schedules Analyst and Investor Plant Visit to Vizag and Kakinada

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 11 Mar 2026, 01:19 PM

Aurobindo Pharma Limited has scheduled an in-person plant visit for a group of analysts and investors on March 16, 2026. The visit will cover the company's facilities in Vizag and Kakinada, running from 9:00 AM to 5:00 PM IST. Such visits are standard practice to allow institutional stakeholders to observe operational infrastructure and manufacturing capabilities. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the interaction.

In-person plant visit scheduled for March 16, 2026, for analyst and investor groups.
The visit will take place at manufacturing sites in Vizag and Kakinada.
The interaction is scheduled for a full day from 09:00 AM to 05:00 PM IST.
Company confirms that no unpublished price sensitive information (UPSI) will be discussed.

💡 This is a routine investor relations event; no immediate action is necessary. Investors may look for subsequent research notes from participating brokerages for qualitative insights into the company's manufacturing operations.

View All AUROPHARMA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 6.3% YoY to INR 8,286 Cr in Q2 FY26. US Formulations grew 2% QoQ to USD 417 million (INR 3,634 Cr). Europe Formulations grew 17.8% YoY to INR 2,480 Cr. Growth Markets grew 8.7% YoY to INR 882 Cr. ARV Formulations surged 68.7% YoY to INR 325 Cr. API business declined 16.9% YoY to INR 961 Cr due to market pricing pressures.

Geographic Revenue Split

US Formulations account for 43.9% of consolidated revenue. Europe contributes approximately 30% (INR 2,480 Cr). Growth Markets represent 10.6% (INR 882 Cr). ARV and API segments contribute 3.9% and 11.6% respectively.

Profitability Margins

Gross Margin improved to 59.7% in Q2 FY26 from 58.8% in Q2 FY25 (up 88 bps), driven by favorable raw material prices and business mix. Net Profit Margin for FY25 stood at 11.0%.

EBITDA Margin

EBITDA for Q2 FY26 was INR 1,678 Cr, representing a 20.3% margin (up 16 bps YoY). Excluding gRevlimid, EBITDA grew 14% QoQ, reflecting strong operating leverage and cost efficiency.

Capital Expenditure

Net CapEx for Q2 FY26 was USD 106 million (approx. INR 890 Cr). The company has committed INR 1,000 Cr for the TheraNym mammalian bioreactor facility and is investing in a new vial filling line at CuraTeQ.

Credit Rating & Borrowing

Debt Equity Ratio is low at 0.08 as of March 2025. Average finance costs declined to 4.7% in Q2 FY26 due to effective treasury management. Interest Coverage Ratio stood at 12.2 in FY25.

⚙️ Operational Drivers

Raw Materials

Key inputs include Coal (for power in Pen-G plant), Beta-lactam intermediates (73% of API sales), and Non-Beta lactam intermediates. Specific chemical names are not disclosed in the available documents.

Import Sources

Sourcing includes China (for European supply ramp-up) and domestic Indian markets. Specific state-level sourcing is not disclosed.

Capacity Expansion

Pen-G facility (Lyfius) is ramping up to 15,000 MT capacity. TheraNym is establishing a 2x15 kL mammalian bioreactor facility expected to be ready by June/July 2026. China plant started invoicing in April 2025 with a goal of triple-digit turnover in 3 years.

Raw Material Costs

Raw material costs are optimized through backward integration (Pen-G plant), which is expected to push gross margins above 60% once fully operational. API pricing pressures impacted revenue by 16.9% YoY.

Manufacturing Efficiency

Fixed Asset Turnover was 2.1 in FY25. The company is targeting 100% capacity utilization at the Pen-G plant to reach 15,000 MT production.

📈 Strategic Growth

Expected Growth Rate

20-21%

Growth Strategy

Growth will be driven by the commercialization of the biosimilar portfolio (CuraTeQ), ramp-up of the Pen-G facility, and the Lannett acquisition in the US. The company aims for USD 1 billion in annual revenue from Europe by FY26 through increased in-house supplies and China plant exports.

Products & Services

Oral Solids, Injectables, Biosimilars (Trastuzumab, Bevacizumab, Denosumab, Omalizumab), ARV formulations, and APIs (Beta-lactam and Non-Beta lactam).

Brand Portfolio

Lyfius (Pen-G), CuraTeQ (Biosimilars), TheraNym (Biologics), Lannett (US acquisition).

New Products/Services

Launched 6 new products and filed 13 ANDAs in Q2 FY26. Biosimilars like Trastuzumab and Bevacizumab have received EC and MHRA approvals.

Market Expansion

Expanding in Growth Markets (Indonesia, China, Brazil, Mexico) and scaling the European business to reach a USD 1 billion milestone by FY26.

Strategic Alliances

Signed a second product contract with MSD (Merck) to support expanded scope in biologics, adding two 15 kL bioreactor lines.

🌍 External Factors

Industry Trends

The industry is shifting toward complex generics and biosimilars. Aurobindo is positioning itself through CuraTeQ and TheraNym to capture the biologics CMO and biosimilar market.

Competitive Landscape

Faces competitive pricing pressures in the API and US generic markets.

Competitive Moat

Moat is built on vertical integration (Pen-G backward integration), a diversified global portfolio (US, Europe, Growth Markets), and a robust pipeline of 13 ANDA filings in a single quarter.

Macro Economic Sensitivity

Sensitive to movements in currency exchange and interest rates. The company reported a small FX gain of INR 5 Cr in Q2 FY26 compared to INR 15 Cr YoY.

Consumer Behavior

Increased demand for affordable ARVs and biosimilars globally is driving volume growth.

Geopolitical Risks

Trade barriers and stricter climate regulations pose transition risks and higher compliance costs.

⚖️ Regulatory & Governance

Industry Regulations

Subject to USFDA, European Commission, and MHRA (UK) regulations for product approvals and manufacturing facility inspections.

Environmental Compliance

The company is investing in energy-efficient technologies and conducting energy audits to align with carbon regulations.

Taxation Policy Impact

Reported tax rate is approximately 35% because tax credits are not taken on losses from new businesses (like Pen-G); the effective tax rate on profitable entities is 25%.